TuHURA Biosciences (HURA) Net Cash Flow (2010 - 2026)

TuHURA Biosciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 141.6% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $78296.0, a 99.57% decrease from a year earlier, with the FY2025 full-year figure at -$9.0 million, down 200.5% from the prior year.
• Net Cash Flow grew to $2.7 million in Q1 2026 per HURA's latest filing, from $949405.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $15.9 million in Q3 2024 and bottomed at -$8.3 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$1.8 million (2023), against an average of -$423437.2.
• Across the five-year window, Net Cash Flow plunged 262.85% in 2022 and surged 1307.81% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$5.4 million in 2022, then jumped by 50.56% to -$2.6 million in 2023, then jumped by 701.68% to $15.9 million in 2024, then tumbled by 94.04% to $949405.0 in 2025, then surged by 182.09% to $2.7 million in 2026.
• Per Business Quant, the three latest HURA Net Cash Flow figures stand at $2.7 million (Q1 2026), $949405.0 (Q4 2025), and -$5.8 million (Q3 2025).